PL2850075T3 - Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c - Google Patents

Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c

Info

Publication number
PL2850075T3
PL2850075T3 PL13720201T PL13720201T PL2850075T3 PL 2850075 T3 PL2850075 T3 PL 2850075T3 PL 13720201 T PL13720201 T PL 13720201T PL 13720201 T PL13720201 T PL 13720201T PL 2850075 T3 PL2850075 T3 PL 2850075T3
Authority
PL
Poland
Prior art keywords
hepatitis
piperazine
piperidine compounds
virus inhibitors
virus
Prior art date
Application number
PL13720201T
Other languages
English (en)
Polish (pl)
Inventor
Daniel D. Long
Robert Murray Mckinnell
Orden Lori Jean Van
Gavin Ogawa
Donna Wilton
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of PL2850075T3 publication Critical patent/PL2850075T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
PL13720201T 2012-04-25 2013-04-24 Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c PL2850075T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637959P 2012-04-25 2012-04-25
US201361774033P 2013-03-07 2013-03-07

Publications (1)

Publication Number Publication Date
PL2850075T3 true PL2850075T3 (pl) 2017-08-31

Family

ID=48237291

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13720201T PL2850075T3 (pl) 2012-04-25 2013-04-24 Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c

Country Status (17)

Country Link
US (1) US9206159B2 (enExample)
EP (1) EP2850075B1 (enExample)
JP (1) JP6069491B2 (enExample)
CN (1) CN104302639B (enExample)
CA (1) CA2869640C (enExample)
CY (1) CY1118920T1 (enExample)
DK (1) DK2850075T3 (enExample)
ES (1) ES2624846T3 (enExample)
HR (1) HRP20170471T1 (enExample)
HU (1) HUE032173T2 (enExample)
LT (1) LT2850075T (enExample)
ME (1) ME02682B (enExample)
PL (1) PL2850075T3 (enExample)
PT (1) PT2850075T (enExample)
RS (1) RS55864B1 (enExample)
SI (1) SI2850075T1 (enExample)
WO (1) WO2013163262A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794454B (zh) * 2017-04-27 2023-08-15 广东东阳光药业股份有限公司 一种咪唑环化合物的制备方法
CN107814789B8 (zh) * 2017-11-27 2021-01-01 常州寅盛药业有限公司 一种达卡他韦起始原料的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY32462A (es) 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
EP2398474A4 (en) 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20180028070A (ko) 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
EP2475254A4 (en) * 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2013515746A (ja) 2009-12-24 2013-05-09 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症の治療又は予防のための類似体
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
JP5891235B2 (ja) * 2010-11-04 2016-03-22 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー C型肝炎ウイルスの新規阻害剤
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20140091036A (ko) 2011-11-03 2014-07-18 세라밴스 인코포레이티드 단편 [2-[4-(바이페닐-4-일)-1h-이미다조-2-일]피롤리딘-1-카르보닐메틸]아민을 포함하는 간상 c형 간염 바이러스 억제제
JP6069492B2 (ja) * 2012-04-25 2017-02-01 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー C型肝炎ウイルス阻害剤

Also Published As

Publication number Publication date
CA2869640A1 (en) 2013-10-31
US9206159B2 (en) 2015-12-08
US20130287730A1 (en) 2013-10-31
EP2850075B1 (en) 2017-02-22
SI2850075T1 (sl) 2017-06-30
ES2624846T3 (es) 2017-07-17
CA2869640C (en) 2018-03-20
DK2850075T3 (en) 2017-05-22
CN104302639B (zh) 2017-03-29
CN104302639A (zh) 2015-01-21
LT2850075T (lt) 2017-05-10
ME02682B (me) 2017-06-20
EP2850075A1 (en) 2015-03-25
WO2013163262A1 (en) 2013-10-31
HUE032173T2 (en) 2017-09-28
CY1118920T1 (el) 2018-01-10
RS55864B1 (sr) 2017-08-31
HRP20170471T1 (hr) 2017-06-02
JP2015514807A (ja) 2015-05-21
PT2850075T (pt) 2017-05-02
JP6069491B2 (ja) 2017-02-01

Similar Documents

Publication Publication Date Title
IL269662A (en) Hepatitis C virus inhibitors
IL221033A0 (en) Hepatitis c virus inhibitors
EP2575819A4 (en) INHIBITORS OF HEPATITIS C VIRUS
ZA201306720B (en) Hepatitis c virus inhibitors
IL229270B (en) Hepatitis c virus inhibitors
IL224298A (en) Hepatitis virus inhibitors c
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
EP2603080A4 (en) HEPATITIS C-VIRUS HEMMER
ZA201309356B (en) Hepatitis c virus inhibitors
LT2897611T (lt) Hepatito c gydymo būdai
ZA201503458B (en) Hepatitis c virus inhibitors
ZA201308011B (en) Processes for preparing inhibitors of the hepatitis c virus
EP2748160A4 (en) INHIBITORY COMPOUNDS OF HEPATITIS C
SI2850075T1 (sl) Piperazin-piperidinske spojine kot inhibitorji virusa hepatitisa C
HK1192541A (en) Hepatitis c virus inhibitors
HK1192882A (en) Hepatitis c virus inhibitors